Merck teams up with cancer startup Foghorn in $425M deal

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 8, 2020 at 11:12 AM.

  1. #1 cafead, Jul 8, 2020 at 11:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via Two years after its official launch, next-gen cancer biotech Foghorn Therapeutics has nabbed a biobucks deal with Big Pharma Merck.

    The Cambridge, Massachusetts-based biotech launched in March 2018 aiming to develop drugs for cancer as well as other serious diseases based on insights into the chromatin regulatory system.

    article source
     
    Quote

Reply to Thread